Avivagen Announces Stock Option Grant
May 21 2014 - 4:09PM
Access Wire
OTTAWA, ON / ACCESSWIRE / May
21, 2014 / Avivagen Inc. (TSXV:VIV), a wellness
company committed to developing and delivering products that
support and improve the health and quality of life for animals and
the people who care for them, today announced that it has granted
options to purchase 1,916,667 common shares to directors and
officers, in accordance with the requirements of the TSX Venture
Exchange. The stock options were granted pursuant to the terms of
Avivagen's stock option plan and are exercisable at $0.07 per
share. The options granted to directors and officers form part of
their total remuneration package and were made as part of a broader
grant which included other members of the Avivagen team.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life
sciences company trading on the TSX Venture Exchange under the
ticker symbol "VIV". The Company's goal is to develop and deliver
scientifically-proven solutions that can truly benefit companion
and production animals by employing natural mechanisms for
maintaining good health. Avivagen's targeted markets include
Livestock Productivity and Pet Wellness.
The company has sites located in
partnership facilities of the National Research Council of Canada
(NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island.
More information can be found at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected
technology is based on its discoveries concerning carotenoid
antioxidants. The novel natural compounds discovered by Avivagen
support the body's own systems to maintain and enhance health,
particularly by supporting immune function. Avivagen's
commercial-stage application of its technology is Fully-Oxidized
beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as
carotenoid oxidation products in vegetation, but in minute amounts.
They have been developed to support the health of companion animals
and for use in the global food animal market.
Research and study results indicate OxC-beta
supports innate immune function, which can help maintain good
health. In pets, OxC-beta supports overall vitality and energy,
mobility and joint function, skin, coat and gut. Results observed
in food animals have included healthier growth, better utilization
of feed and decreased mortality. In food animals, it is intended
that use of OxC-beta avoids the feeding of antibiotics.
The commercial products of Avivagen are
OxC-beta for livestock, Vivamune(TM) Health Chews and Oximunol(TM)
Chewables.
About OxC-beta for
Livestock
OxC-beta for Livestock is available as a 10%
pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million
addition to animal feeds, in accordance with producer-developed
protocols. In past studies, OxC-beta has been shown to support
health and growth in species such as fish, chicken, pigs and
cattle. OxC-beta for livestock is currently available for
commercial sale in the Kingdom of Thailand.
About Vivamune(TM) Health
Chews - For dogs and cats
Vivamune(TM) Health Chews, containing
Avivagen's proprietary active ingredients, are
scientifically-formulated chews for dogs and cats. Vivamune(TM)
Health Chews work with a pet's own immune system to maintain
overall health and well-being. They are sold in re-sealable
packages of 30 chews and are currently available in the United
States by ordering on-line at
www.vivamunehealth.com.
About Oximunol(TM)
Chewables - For dogs
Oximunol(TM) Chewables are
scientifically-formulated chewable tablets that contain Avivagen's
proprietary, patented active ingredient OxC-beta. OxC-beta has been
shown to stimulate innate cellular immunity and may thereby help to
maintain overall health and well-being. Oximunol(TM) Chewables are
distributed by Bayer Healthcare LLC and are available through
veterinarians for dogs of all ages in the United States.
Forward
Looking Statements
This document includes certain
forward-looking statements that are based upon current
expectations, which involve risks and uncertainties associated with
the business of Avivagen Inc. and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions "will", "anticipate",
"believe", "plan", "estimate", "expect", "intend", and similar
expressions. Forward-looking statements are subject to a number of
risks and uncertainties that could cause actual results or events
to differ materially from current expectations. Unless required by
law, Avivagen Inc. assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
c.groome@avivagen.com
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
SOURCE: Avivagen Inc.
-----------------
|Copyright© 2014|
|Avivagen |
-----------------
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jul 2023 to Jul 2024